Dublin, Feb. 23, 2023 (GLOBE NEWSWIRE) -- The "Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
The global head and neck cancer therapeutics market size is expected to reach USD 3.5 billion by 2030. The market is expected to expand at a CAGR of 12.5% from 2022 to 2030.
Companies Mentioned
- Eli Lilly and Company
- Sanofi
- Merck & Co. Inc.
- Clingen Group plc.
- Bristol-Mayers Squibb Company
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd
- F. Hoffmann-La Roche Ltd.
Increasing advancements in the diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth, as they are cost-effective and more specific to target over surgeries. The increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of the market.
According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide.
Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease.
Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm's Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA.
Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.
Head And Neck Cancer Therapeutics Market Report Highlights
- By therapy type, the immunotherapy segment held the largest market share in 2021 due to the presence of supportive reimbursement policies and the higher efficacy of immunotherapy drugs as an effective treatment for head and neck cancer diseases
- By route of administration, the oral segment is expected to be the fastest-growing segment during the forecast period. This can be attributed to the high safety, efficacy, and tolerability associated with this route of administration among rare disease patients
- By distribution channel, the retail and specialty pharmacy segment dominated the market in 2021. This dominance can be attributed to the preference of oncologists for specialty pharmacies. Oncologists often need specialty pharmacies so that with extensive therapeutic knowledge, they can support treatment plans and relieve them from the administrative burden
- Asia Pacific is expected to be the fastest-growing region during the forecast period. The growth of the region can be attributed to the entry of new products into the region. For instance, in 2020, NMPA approved ERBITUX (Cetuximab) developed by Merck and Co., Inc., to treat patients with head and neck cancer in China
Report Metrics
| Report Attribute | Details |
| No. of Pages | 120 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value (USD) in 2022 | $1.37 Billion |
| Forecasted Market Value (USD) by 2030 | $3.5 Billion |
| Compound Annual Growth Rate | 12.5% |
| Regions Covered | Global |
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Head and Neck Cancer Therapeutics Market - Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers Analysis
3.3.1.1 Increasing prevalence of head and neck cancers
3.3.1.2 Rising geriatric population
3.3.1.3 Increasing R&D and strong presence of pipeline product
3.3.1.4 Supportive reimbursment policies and rising awareness about disease
3.3.2 Market Restraint Analysis
3.3.2.1 Paucity of data related to safety and efficacy
3.3.2.2 High cost of treatments
3.4 Head and Neck Cancer Therapeutics Market Analysis Tools
3.4.2 Industry Analysis - Porter's
3.4.3 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.4.3.1 Political and Legal
3.4.3.2 Economic & Social
3.4.3.3 Technological
3.5 Reimbursement & Regulatory Scenario
3.6 Major Deals & Strategic Alliances
3.7 Pipeline analysis
Chapter 4 Head and Neck Cancer Therapeutics Market Analysis: Therapy Type Scope, 2018 - 2030 (Revenue, USD Million)
4.1 Head and Neck Cancer Therapeutics Market: Therapy Type Movement Analysis
4.2 Chemotherapy
4.2.1 Chemotherapy market estimates and forecast, 2018 - 2030 (USD million)
4.3 Immunotherapy
4.3.1 Immunotherapy market estimates and forecast, 2018 - 2030 (USD million)
4.4 Targeted Therapy
4.4.1 Targeted therapy market estimates and forecast, 2018 - 2030 (USD million)
Chapter 5 Head and Neck Cancer Therapeutics Market Analysis: Route of Administration Scope, 2018 - 2030 (Revenue, USD Million)
5.1 Head and Neck Cancer Therapeutics Market: Route of Administration Movement Analysis
5.2 Injectables
5.2.1 Injectables market estimates and forecast, 2018 - 2030 (USD million)
5.3 Oral
5.3.1 Oral market estimates and forecast, 2018 - 2030 (USD million)
Chapter 6 Head and Neck Cancer Therapeutics Market Analysis: Distribution Channel Scope, 2018 - 2030 (Revenue, USD Million)
6.1 Head and Neck Cancer Therapeutics Market: Distribution Channel Movement Analysis
6.2 Retail & Specialty Pharmacies
6.2.1 Retail & specialty pharmacies market estimates and forecast, 2018 - 2030 (USD million)
6.3 Hospital Pharmacies
6.3.1 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD million)
6.4 Online Pharmacies
6.4.1 Online pharmacies market estimates and forecast, 2018 - 2030 (USD million)
Chapter 7 Head and Neck Cancer Therapeutics Market Analysis, Regional Scope, 2017-2030, (Revenue, USD Million)
Chapter 8 Head and Neck Cancer Therapeutics Market: Competitive Analysis
8.1 Recent Developments and Impact Analysis, by Key Market Participants
8.1.1 Ansoff matrix`
8.2 Company Categorization
8.2.1 Innovators
8.2.2.1 Market Differentiators
8.3 Vendor Landscape
8.3.1 List of Key Distributors And Channel Partners
8.3.2 Key Customers
8.3.3 Key Company Market Share Analysis, 2020
8.4 Public Companies
8.4.1 Comapany Market Position analysis
8.4.2 Competitive dashboard analysis
8.5 Private Companies
8.5.1 List of Key Emerging Companies
8.6 Regional Network Map
8.8 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/7gftlq-and-neck?w=12
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
